What Happens When You Stop Taking GLP-1s? The Weight Regain Data

Health information disclaimer: This article is for general information only and is not medical advice. Never start, stop, or change the dose of a prescription weight-loss medication without talking to your prescriber. Information is current as of October 2026 and reflects research available in Canada; drug availability, coverage, and clinical guidance may differ by province.

Here is the uncomfortable truth about GLP-1 drugs that the success stories skip: they work brilliantly while you take them, and the weight comes back fast when you stop. Not slowly. Not partially. Fast, and nearly all of it, according to the best 2026 data we have.

This is not a reason to avoid these medications. It is a reason to plan. Obesity behaves like a chronic condition, and researchers increasingly describe GLP-1 therapy the same way: an ongoing intervention, not a finite course with a finish line. Understanding the regain curve before you ever stop is what separates people who keep their results from people who yo-yo.

Key takeaways

• A January 2026 BMJ meta-analysis (37 studies, 9,341 participants) found weight returns at about 0.8 kg per month after stopping semaglutide or tirzepatide, roughly four times faster than after behavioral programs.
• On average, about two-thirds of lost weight is regained within a year of stopping, with return to baseline projected at around 1.5 years.
• Cardiometabolic benefits (blood sugar, blood pressure, cholesterol) fade even sooner, returning to baseline in about 1.4 years.
• Real-world data are less bleak than trial projections: about 45 percent of patients in a large Cleveland Clinic study maintained or continued their weight loss a year after stopping, largely by restarting, switching, or getting structured lifestyle support.
• An estimated 50 to 65 percent of patients discontinue within the first year, so planning the "after" is not pessimism, it is statistics.

The numbers: what the 2026 research found

The landmark analysis, led by Oxford researchers and published in The BMJ on January 7, 2026, pooled 37 studies covering 9,341 participants across all types of weight-loss medications. The findings for the newer GLP-1 drugs were striking:

• Regain rate: about 0.8 kg (roughly 1.75 lb) per month after stopping semaglutide or tirzepatide, a steady, near-linear climb rather than a sudden bounce.
• Four times faster than the regain seen after stopping behavioral weight-loss programs, and faster than after bariatric surgery programs too.
• Two-thirds of lost weight regained within the first year after stopping, on average about 9.9 kg in that year.
• Return to baseline weight projected at around 1.5 years for GLP-1 stoppers (1.7 years across all weight-loss medications in the analysis).
• Health benefits fade first: improvements in glycaemia, blood pressure, total cholesterol, and triglycerides were projected to return to baseline within about 1.4 years.

Study co-author Susan Jebb's summary was blunt: the drugs are highly effective and valuable, but obesity is a chronic relapsing condition, and some form of continued treatment or intervention is needed to sustain the benefits.

One important nuance: these are averages across trial populations, and the authors stress that a small number of people maintain sustained weight loss after stopping. Averages describe the centre of a wide distribution, not your destiny.

The real-world picture is softer (with a catch)

Trial data show what happens when people stop and receive no further structured help. Real life is messier, and a large Cleveland Clinic study suggests it can also be kinder.

The retrospective study followed 7,938 adults in Ohio and Florida who started injectable semaglutide or tirzepatide and stopped within 3 to 12 months. Among those treated for obesity, who had lost an average of 8.4 percent of body weight before stopping, the average regain one year later was just 0.5 percent of body weight. About 45 percent maintained their loss or kept losing. Patients treated for type 2 diabetes did even better on average.

The catch, as lead researcher Hamlet Gasoyan noted, is that "stopping" rarely meant "no further treatment." In the cohort, 27 percent switched to an alternative obesity medication, 20 percent restarted their original medication, and 14 percent pursued lifestyle modification with a healthcare professional. The softer landing came from continued care, not from willpower alone.

The lesson is not that the BMJ projections are wrong. It is that stopping the drug and stopping treatment are different things, and the people who plan the transition do meaningfully better.

Why the rebound happens

The regain is physiological, not a character flaw. GLP-1 drugs suppress appetite and quiet "food noise" by acting on brain and gut hormone pathways. Remove the drug, and those signals return: hunger rises, satiety fades, and the body's weight-regulation systems push back toward the previous set point. This is the same biology that makes keeping weight off after any major loss difficult; the drugs just make the contrast sharper because the "on" state was so effective.

That is also why researchers now frame the conversation around chronic management. Nobody asks when you will "finish" blood pressure medication. The emerging consensus treats long-term obesity pharmacotherapy similarly: the question is not whether you stop, but what ongoing strategy, dose, or combination keeps you healthy at sustainable cost.

Habits that protect your results

Whether you stay on treatment, taper, or stop, these habits are associated with better long-term outcomes:

Keep the protein high and keep lifting. Weight regain after stopping tends to be disproportionately fat, which is the worst trade: weight back, muscle not. Continuing resistance training 2 to 4 times per week with protein around 1.2 to 1.6 g per kg daily protects body composition during the transition: trial evidence shows resistance training roughly halves the share of weight lost as lean mass compared with dieting alone.

Weigh yourself regularly, without drama. Self-monitoring is one of the most consistent predictors of maintenance across all weight-loss research. A weekly weigh-in catches a 2 kg drift while it is still a 2 kg drift.

Protect sleep and manage stress. Short sleep and chronic stress both drive hunger hormones in exactly the wrong direction during a vulnerable transition. Unsexy, effective.

Keep the food environment you built. The meal structure, grocery habits, and portion patterns that worked on the drug are the infrastructure of maintenance. If the drug made healthy eating effortless, the task now is making it habitual: regular mealtimes, protein at every meal, planned rather than impulsive eating.

Stay in care. The Cleveland Clinic data point in one direction: people who kept some form of clinical contact, a restart, a switch, or structured lifestyle support, did far better than people who simply stopped. Book the follow-up appointment before you stop, not after the regain starts.

Move daily, in ways you enjoy. Winter running, walking, cycling, swimming: the best exercise for maintenance is the one you will still be doing in a year. Consistency beats intensity here.

If you are thinking about stopping: a planning checklist

1. Talk to your prescriber first. Discuss why you want to stop (cost, side effects, goal reached, side-effect burden) because each reason points to a different plan: dose adjustment, a switch, a taper, or a structured maintenance program.
2. Ask about tapering or maintenance dosing rather than abrupt discontinuation.
3. Line up the next step before the last dose: a follow-up appointment in 4 to 6 weeks, a dietitian referral, or an alternative therapy.
4. Set a regain threshold in advance. Agree with your clinician on a weight regain level that triggers re-evaluation, so a small drift prompts action instead of shame.
5. Check your coverage. In Canada, private and public coverage for these drugs varies widely; cost-driven discontinuation is common, and knowing your options (including patient support programs) before a gap in treatment beats scrambling after one.

Practical next steps

• On a GLP-1 now: start the maintenance habits today, while the drug is helping. Protein targets, strength training, and regular weigh-ins are easier to build now than during a transition.
• Considering stopping: book the conversation with your prescriber this month, and go in with the checklist above.
• Already stopped and regaining: this is expected physiology, not failure. Re-engage with your clinician; restarting, switching, or adding structured support are all normal, evidence-backed next steps.
• Supporting someone else: skip the judgment. The data say regain is the default outcome of stopping without a plan, and support beats shame for getting back on track.

The bottom line

Stopping a GLP-1 without a plan leads, on average, to rapid regain: about 0.8 kg a month, two-thirds of lost weight back within a year, health benefits fading even sooner. But "on average" is not destiny. The people who keep their results are the ones who treat obesity as the chronic condition the evidence says it is: they stay in care, keep training, keep protein high, monitor, and have a plan for the transition before it happens. The drug was never the whole treatment. The plan is.

Sources

• West et al., The BMJ, January 7, 2026 (meta-analysis of 37 studies, 9,341 participants, on weight regain after stopping weight-loss medications): https://medscape.com/viewarticle/weight-regain-health-benefit-loss-rapid-when-glp-1s-stopped-2026a10000kr
• Medscape, "Solutions Emerging for Post-GLP-1 Weight Regain" (BMJ analysis details, discontinuation rates): https://www.medscape.com/viewarticle/solutions-emerging-post-glp-1-weight-regain-2026a1000ine
• Cleveland Clinic retrospective cohort (7,938 patients; real-world discontinuation outcomes), via Bariatric News: https://www.bariatricnews.net/post/discontinuing-semaglutide-and-tirzepatide-on-average-does-not-lead-to-significant-weight-regain
• Drug Topics, "Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide": https://www.drugtopics.com/view/model-finds-weight-regain-after-stopping-semaglutide-or-tirzepatide
• TechBuzz Ireland, "The Weight Regain Curve After Stopping GLP-1 Therapy" (first-year trajectory, 9.9 kg average regain): https://techbuzzireland.com/2026/09/11/the-weight-regain-curve-after-stopping-glp-1-therapy-and-what-it-means-for-long-term-planning/
• eMarketer, "Stopping GLP-1s leads to rapid rebound": https://www.emarketer.com/content/consumers-who-stop-glp-1-medications-quickly-regain-weight-lose-health-benefits